MedTrace Logo

An Observational Study on the Impact of the 23-valent Pneumonia Vaccine on Lung Cancer Patients

NCT07142057 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2025-08-26

No results posted yet for this study

Summary

To evaluate the impact of the 23-valent pneumonia vaccine on the incidence of pulmonary infection and survival in lung cancer patients, and to explore its preventive effect and safety in the lung cancer patients.

Conditions

Interventions

BIOLOGICAL

23-valent pneumococcal vaccine

Receive the 23-valent pneumococcal vaccine; Do not receive the 23-valent pneumococcal vaccine

Sponsors & Collaborators

  • The First Affiliated Hospital of Guangzhou Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-01
Primary Completion
2027-09-01
Completion
2030-09-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07142057 on ClinicalTrials.gov